title: The 2001 serological survey in the Czech Republic--mumps.
abstract: In total, 3,010 sera from a representative population sample of the Czech Republic aged from 1 to 64 years were tested according to the requirements of the ESEN 2 project using a commercial kit Mumps IgG (II) EIA manufactured by Denka Seiken, Japan. To date, the regular programme of vaccination against mumps has covered the population of children under 15 years of age. The vaccination coverage achieved (97-100%) does not correspond to the antibody prevalence rates of 70.2 to 86.4% as found. After implementation of regular vaccination in 1987, the morbidity rates have fallen dramatically. Nevertheless, the collective immunity achieved is not sufficient to prevent epidemics of mumps.
authors.affiliation: Centre of Epidemiology and Microbiology, NRL for mumps, measles and rubella, National Institute of Public Health, Prague, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Mrázová
authors.forename: M
authors.initials: M
authors.lastname: Smelhausová
authors.forename: Z
authors.initials: Z
authors.lastname: Sestáková
authors.forename: E
authors.initials: E
authors.lastname: Svandová
authors.forename: C
authors.initials: C
authors.lastname: Benes
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D018153:Czech Republic / Q000453:epidemiology; D003625:Data Collection; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D009107:Mumps / Q000097:blood / Q000453:epidemiology* / Q000276:immunology; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000276:immunology; D009109:Mumps virus / Q000276:immunology; D012698:Serologic Tests
chemical_list: D000914:Antibodies, Viral; D009108:Mumps Vaccine